VBL Therapeutics
Manufacturing · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
8 Hasatat St, Modi'in, Central District,...Phone Number
+972 89935000Website
www.vblrx.comRevenue
<$5 MillionStock Symbol
VBLTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL's lead oncology product candidate, ofranergene obadenovec (VB-111), is a targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VBL Therapeutics is headquartered in Israel.Explore more
VBL Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VBL Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on VBL Therapeutics recently announced quarterly report
VBL Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at VBL Therapeutics
Funding: Get notified immidiatlly once VBL Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check if VBL Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if VBL Therapeutics is spiking on competitors!
Product Launch: Get notified when VBL Therapeutics launches new products
Click to see if VBL Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined VBL Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
VBL Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
VBL Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about VBL Therapeutics.
VBL Therapeutics financials insights
Gather financial insights about VBL Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$40M
VBL Therapeutics Tech Stack
A closer look at the technologies used by VBL Therapeutics
Most Recent Scoops
Earnings
Pain Point
Pain Point
Earnings
Sustainability, Patient Experience, Telemedicine
Earnings
Clinical Operations, Operations
Earnings
Pharmaceuticals
Earnings
Manufacturing Operations, Operations
VBL Therapeutics News & Media
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company. VBL intends to include the proceeds in the Agreement and Plan of Merger entered into with Notable Labs Inc., announced on February 23, 2023.Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
REHOVOT, Israel--(BUSINESS WIRE)-- #COP26--Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today announced that it has acquired a manufacturing facility in Modi’in, Israel, and certain related assets from biotechnology company VBL Therapeutics (Nasdaq: VBLT). In addition, Aleph Farms has signed a Memorandum of Understanding (MOU) with ESCO Aster, a vertically-integrated contract manufacturing organization, to produce cultivated meat in Singapore. ThSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLT
NEW YORK, Feb. 27, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VBL Therapeutics
Sign Up For FreeTo access detailed company insights
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL's lead oncology product candidate, ofranergene obadenovec (VB-111), is a targeted anti-cancer gene-therapy agent that is being developed to tre... Read More
